CJC-1295 No DAC + Ipamorelin is a strategic pairing of two distinct growth hormone secretagogues that operate through complementary mechanisms. CJC-1295 No DAC is a GHRH (growth hormone-releasing hormone) analog with enhanced α-helical structure and 49-fold greater potency than native GHRH in pituitary cells, activating the GHRH receptor pathway. Ipamorelin is a selective GHRP (growth hormone-releasing peptide) that activates the ghrelin receptor (GHS-R1a), demonstrating unique selectivity for GH release without stimulating ACTH or cortisol. The scientificrationale for combining these peptides stems from research demonstrating that GHRH and GHRP pathways act synergistically: GHRH primarily stimulates GH synthesis and amplifies GH pulse amplitude, while GHRPs modulate pulse frequency and timing by acting on distinct receptors and intracellular signaling cascades. When combined, these complementary mechanisms can produce GH release exceeding the sum of individual effects—a phenomenon documented across multiple preclinical models. This synergistic interaction reflects the physiological architecture of GH regulation, where multiple signaling pathways converge on pituitary somatotrophs to coordinate pulsatile GH secretion patterns.
 
Key Ingredients and Functions:
 
CJC-1295 (No DAC): Mimics Growth Hormone-Releasing Hormone (GHRH), telling the pituitary to release GH. "No DAC" means it doesn't have the Drug Affinity Complex, making it more natural in its release pattern.
Ipamorelin:  Is a Growth Hormone-Releasing Peptide (GHRP) that triggers GH release and blocks somatostatin (the hormone that stops GH), increasing the pulse of growth hormone.